BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...

The global down syndrome market is expected to reach US$ 3,775.8 Million by 2030. The market is expected to experience the growth rate of 17.3% from 2021 to 2030. Request To Download Sample of This ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Our analysis of options history for Biogen BIIB revealed 12 unusual trades. Delving into the details, we found 25% of traders ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

The 2024 MM+M Agency 100 honoree tapped Coman for the top spot in order to lead clients across the industry through a new era ...

Biogen Inc. (NASDAQ:BIIB) also benefits from its strong pipeline, which shows promise in areas like lupus and Alzheimer’s ...

Panelists in this recent #TrendTalks discussion, “Activating Omnichannel Without Omniburden, sponsored by Relevate Health,” ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...